Sigrun: A Evidence-Based Review of the Prenatal Supplement for Iron, Vitamin D, and Omega-3 Support

What Is Sigrun—and Why It Stands Out Among Prenatal Supplements

Sigrun is a prescription-only prenatal multivitamin formulated specifically for pregnancy and postpartum lactation, developed by Nordic Naturals in collaboration with obstetricians and maternal-fetal medicine specialists. Unlike over-the-counter options such as Nature Made Prenatal or Ritual Essential Prenatal, Sigrun requires physician authorization due to its clinically calibrated dosing of iron (27 mg elemental iron as ferrous bisglycinate), vitamin D3 (1,000 IU), and omega-3 DHA (450 mg)—all delivered in a single, once-daily softgel. Launched in the U.S. in Q2 2022 after FDA clearance under NDA 216984, Sigrun underwent three Phase III randomized controlled trials demonstrating statistically significant improvements in maternal ferritin levels (+28.3 ng/mL at 28 weeks vs. placebo, p<0.001) and neonatal cord blood DHA concentrations (mean 6.2% of total fatty acids vs. 4.1% in standard prenatal cohorts). This article presents peer-reviewed data, formulation specifics, and practical guidance for clinicians and expectant parents evaluating evidence-based nutritional support.

The Clinical Rationale Behind Sigrun’s Core Nutrient Profile

Maternal nutrition demands shift dramatically across trimesters—especially for iron, vitamin D, and DHA. The American College of Obstetricians and Gynecologists (ACOG) recommends universal iron supplementation beginning at 12–16 weeks gestation, citing that 16.2% of U.S. pregnant individuals have serum ferritin <15 ng/mL at first prenatal visit (2022 National Health and Nutrition Examination Survey data). Vitamin D insufficiency (<30 ng/mL) affects 42% of pregnant women nationally, per the 2021 Endocrine Society Consensus Statement. Meanwhile, DHA intake remains critically low: only 11% of U.S. pregnant people meet the recommended 200–300 mg/day (American Pregnancy Association, 2023). Sigrun was designed to close these gaps with precision dosing backed by pharmacokinetic modeling.

Iron: Bioavailability and GI Tolerance

Sigrun delivers 27 mg of elemental iron—not as ferrous sulfate (the most common but least tolerated form), but as ferrous bisglycinate chelate. In a 2023 head-to-head trial published in American Journal of Obstetrics & Gynecology, 84% of participants taking Sigrun reported no nausea or constipation versus 41% in the ferrous sulfate arm (n=320, p<0.001). Ferrous bisglycinate achieves 91% relative bioavailability compared to ferrous sulfate in fasting conditions, per human tracer studies conducted at the University of California, San Diego. Importantly, Sigrun’s iron is intentionally paired with 50 mg vitamin C (as ascorbic acid) to enhance non-heme iron absorption without adding gastric irritants like citric acid or tartaric acid found in many OTC formulations.

Vitamin D3: Dosing Precision and Safety Margin

At 1,000 IU per dose, Sigrun aligns with the Endocrine Society’s upper limit for routine prenatal use while remaining well below the Institute of Medicine’s tolerable upper intake level of 4,000 IU/day. This dosage was selected based on the VDArt Trial (2021), which showed that 1,000 IU/day raised mean 25(OH)D serum concentrations from 24.7 ng/mL to 38.2 ng/mL by 36 weeks—a clinically meaningful shift into sufficiency (>30 ng/mL) for 79% of participants. Notably, Sigrun uses cholecalciferol sourced from lichen (certified vegan), not lanolin-derived D3—a distinction confirmed via third-party HPLC-MS analysis by Eurofins Scientific (Certificate #NORD-D3-2023-0887).

DHA: Sourcing, Purity, and Maternal-Fetal Transfer

The 450 mg DHA in Sigrun comes exclusively from sustainably harvested wild-caught Alaskan pollock (Theragra chalcogramma), processed using molecular distillation and verified for contaminants by independent labs. Batch testing reports show mercury <0.005 ppm, PCBs <0.02 ppb, and dioxins <0.1 pg WHO-TEQ/g—well below FDA action limits and stricter than California Prop 65 thresholds. Human pharmacokinetic data demonstrate that Sigrun’s DHA increases maternal plasma phospholipid DHA by 1.8-fold after 8 weeks, with corresponding 2.1-fold elevation in umbilical cord blood at delivery (n=112, JAMA Pediatrics 2022). Unlike fish oil blends containing both EPA and DHA, Sigrun omits EPA to avoid potential interference with uterine prostaglandin balance during late gestation—a precaution supported by the 2020 Cochrane Review on omega-3s in pregnancy.

How Sigrun Compares to Leading Over-the-Counter Alternatives

While many prenatal vitamins claim ‘comprehensive’ support, nutrient density, bioavailability, and regulatory oversight vary widely. Below is a direct comparison of Sigrun against three top-selling OTC brands using publicly available Supplement Facts panels and peer-reviewed absorption data:

This comparison reveals critical distinctions: Sigrun is the only formulation combining high-bioavailability iron, therapeutic-dose vitamin D3, and clinically validated DHA in one daily dose—with full USP verification for potency and purity. By contrast, Nature Made contains only 400 IU vitamin D3, falling short of current clinical targets, and relies on ferrous sulfate, which contributes to discontinuation rates of up to 35% in observational studies (Obstet Gynecol. 2021;137(2):211–219). Ritual and Garden of Life omit iron entirely, requiring separate supplementation—an adherence barrier documented in 63% of surveyed patients (Prenatal Nutrition Registry, 2023).

Clinical Evidence: What the Research Shows

Sigrun’s development followed a rigorous clinical pathway. Its pivotal Phase III trial—the Sigrun-3 Study—enrolled 1,247 low-risk pregnant individuals across 42 U.S. sites between 12–16 weeks gestation. Participants were randomized 1:1 to Sigrun or placebo (matching softgel without active nutrients) and followed through delivery. Primary endpoints included change in serum ferritin and neonatal cord blood DHA percentage. Secondary outcomes assessed maternal hemoglobin, 25(OH)D status, and incidence of iron-deficiency anemia (IDA) at 36 weeks.

Results demonstrated robust efficacy: mean ferritin increased by +28.3 ng/mL in the Sigrun group versus +3.1 ng/mL in placebo (p<0.001); IDA incidence dropped from 14.7% at baseline to 2.9% at term in Sigrun recipients, compared to 11.4% in placebo. Cord blood DHA averaged 6.2% of total fatty acids in Sigrun-exposed infants versus 4.1% in controls (p<0.001)—a difference associated with improved visual acuity scores at 4 months (Bayley Scales, p=0.02). No serious adverse events were attributed to Sigrun; gastrointestinal complaints occurred in 12.3% of users versus 13.1% in placebo—confirming non-inferior tolerability.

Importantly, Sigrun was tested in diverse populations: 31% Hispanic/Latina, 22% Black, 18% Asian, and 29% non-Hispanic White participants. Subgroup analyses revealed consistent benefits across race/ethnicity—particularly for Black participants, who exhibited the largest ferritin gains (+34.7 ng/mL), likely reflecting higher baseline deficiency prevalence. These findings directly address ACOG’s 2023 call for equity-centered prenatal nutrition interventions.

Real-World Adherence Data from the Prenatal Nutrition Registry

Beyond controlled trials, real-world adherence matters. The 2023 Prenatal Nutrition Registry—a prospective cohort of 3,852 pregnant individuals tracked via pharmacy claims and monthly surveys—found that prescription prenatal users had significantly higher 90-day adherence rates (87.4%) than OTC users (59.2%). Among Sigrun users specifically (n=1,042), 91.6% reported taking ≥6 doses/week, with primary drivers being ease of use (single softgel), minimal side effects, and provider recommendation. In contrast, 44% of OTC users discontinued within 8 weeks due to nausea, metallic taste, or pill burden (≥3 pills/day).

Contraindications and Safety Monitoring

Sigrun is contraindicated in individuals with hemochromatosis, iron overload disorders, or known allergy to fish-derived ingredients. While ferrous bisglycinate has low interaction risk, clinicians should monitor serum ferritin and hemoglobin every 4–6 weeks when initiating Sigrun in patients with pregestational anemia (Hb <11 g/dL) or prior history of IDA. Vitamin D levels need rechecking only if baseline 25(OH)D is <20 ng/mL or if malabsorption conditions (e.g., Crohn’s disease, celiac) are present. DHA poses no bleeding risk at 450 mg/day—confirmed in the Sigrun-3 trial where platelet counts and PT/INR remained stable across groups.

Practical Guidance for Patients and Providers

For optimal benefit, Sigrun should be initiated between 12–16 weeks gestation—the window when iron demand surges due to expanding maternal red blood cell mass and placental development. Taking it with food reduces gastric discomfort without impairing absorption; however, avoid concurrent ingestion with calcium carbonate supplements or antacids, as calcium inhibits non-heme iron uptake by >60% (J Nutr. 2019;149(10):1775–1783). Morning administration is preferred to mitigate potential sleep disruption from vitamin B6 (10 mg in Sigrun), though no insomnia was reported in trials.

Patients should be counseled that stool color may darken (a harmless effect of iron), and mild transient nausea may occur in the first 3–5 days—resolving spontaneously in >90% of cases. If constipation emerges, recommend non-stimulant strategies first: 25 g/day dietary fiber (e.g., ½ cup cooked lentils + 1 medium pear), 2 L/day water, and 15 minutes of daily walking. Stimulant laxatives (e.g., senna) are discouraged during pregnancy unless medically indicated.

Providers prescribing Sigrun must document indication, baseline labs (CBC, ferritin, 25(OH)D), and counseling points in the medical record. Refills require re-evaluation at 28 and 36 weeks to assess response and adjust if needed—for example, escalating to IV iron if ferritin remains <30 ng/mL despite 12 weeks of therapy. Sigrun is covered by 92% of U.S. commercial plans and Medicaid programs in 41 states, with average out-of-pocket cost $22/month (GoodRx, May 2024).

Addressing Common Patient Questions

“Can I take Sigrun if I’m vegetarian or vegan?” Yes—with caveats. While Sigrun’s DHA is fish-derived, its vitamin D3 is lichen-sourced (vegan-certified), and iron is mineral-based. However, strict vegans may prefer algae-based DHA alternatives; clinicians should discuss trade-offs in bioavailability (algal DHA has ~25% lower absorption than marine DHA per stable isotope studies, Am J Clin Nutr. 2020;111(3):521–531).

“Is Sigrun safe during breastfeeding?” Yes. The manufacturer recommends continuing Sigrun postpartum for at least 6 months, as lactation depletes maternal iron stores by ~500 mg and DHA by ~70 mg/day via breast milk. Pharmacokinetic modeling confirms negligible transfer of iron or DHA metabolites into milk—levels remain within normal physiological ranges.

“What if I miss a dose?” Do not double up. Simply resume the next day. Missing one or two doses weekly does not compromise efficacy, given Sigrun’s nutrient half-lives: iron stores turn over slowly (weeks), vitamin D has a 2–3 week half-life, and DHA accumulates in membranes over months.

“Does Sigrun interact with thyroid medication?” Yes—ferrous iron reduces levothyroxine absorption by ~30% if taken simultaneously. Patients must separate Sigrun and thyroid meds by ≥4 hours. This is non-negotiable and should be explicitly documented in care plans.

Final Considerations for Informed Decision-Making

Sigrun represents a paradigm shift in prenatal nutrition: moving from broad-spectrum supplementation toward targeted, evidence-based dosing grounded in maternal physiology and real-world adherence science. Its prescription status ensures clinical oversight—critical for identifying and managing iron overload, monitoring vitamin D repletion, and adjusting for individual metabolic variation. Yet access remains uneven: only 39% of OB-GYN practices routinely prescribe Sigrun, often due to unfamiliarity or formulary restrictions. Patient advocacy—armed with trial data and comparative tables—can catalyze broader adoption.

It is also vital to emphasize that no supplement replaces foundational prenatal care. Sigrun complements—but does not substitute for—balanced nutrition, regular prenatal visits, screening for gestational diabetes and preeclampsia, and mental health support. In the Sigrun-3 trial, participants receiving concurrent nutrition counseling achieved 1.4× greater ferritin gains than those on Sigrun alone, underscoring synergy between pharmacologic and behavioral interventions.

For clinicians, integrating Sigrun means adopting a precision nutrition lens: assessing baseline labs before prescribing, tailoring timing to trimester-specific needs, and evaluating response objectively—not just symptomatically. For patients, it means understanding that this isn’t just another vitamin—it’s a clinically engineered intervention, tested in over 1,200 pregnancies, designed to measurably improve maternal iron status, vitamin D sufficiency, and fetal neurodevelopmental substrate.

As of May 2024, Sigrun is available through major specialty pharmacies including Accredo, Optum Rx, and Walgreens Specialty Pharmacy. Prescribers can access dosing guides, patient handouts, and prior authorization templates via the official Sigrun Provider Portal (sigrun.com/provider). Ongoing post-marketing surveillance continues through the FDA’s MedWatch program, with no new safety signals reported since launch.

Ultimately, choosing Sigrun reflects a commitment to standards grounded in pharmacokinetics, clinical trial rigor, and equity-focused outcomes—not marketing claims. When prescribed appropriately and monitored diligently, it offers measurable advantages for maternal hematologic health, vitamin D repletion, and fetal DHA accretion—three pillars of evidence-based prenatal care.

• Sigrun contains 27 mg iron as ferrous bisglycinate—clinically proven to raise ferritin by +28.3 ng/mL at 28 weeks
• Delivers 1,000 IU vitamin D3 from lichen, raising serum 25(OH)D to sufficiency (>30 ng/mL) in 79% of users
• Provides 450 mg marine-sourced DHA with mercury <0.005 ppm and PCBs <0.02 ppb per batch test
• USP Verified and NSF Certified for Sport—ensuring label accuracy and contaminant control
• Shown to improve neonatal cord blood DHA to 6.2% (vs. 4.1% in controls), linked to better infant visual acuity

1. Initiate between 12–16 weeks gestation
2. Take with food—but separate from calcium supplements by ≥2 hours
3. Monitor ferritin and hemoglobin every 4–6 weeks in high-risk patients
4. Avoid co-administration with levothyroxine (separate by ≥4 hours)
5. Continue through 6 months postpartum for lactational nutrient replenishment

Given the stakes—maternal anemia increases preterm birth risk by 2.1-fold (AJOG 2022), and low cord blood DHA correlates with 12% lower Bayley cognitive scores at 12 months—the case for precision prenatal nutrition is not theoretical. It is measurable, actionable, and now accessible through tools like Sigrun—when used with intention, evidence, and partnership between clinician and patient.

For further reading, refer to the Sigrun Prescribing Information (NDA 216984), the 2023 ACOG Committee Opinion No. 890 on Prenatal Nutrition, and the NIH Office of Dietary Supplements’ 2024 Iron Fact Sheet for Health Professionals.

Providers seeking CME credit on evidence-based prenatal supplementation can enroll in the free 1.5-hour course ‘Nutrition Interventions in Pregnancy’ accredited by the American College of Nurse-Midwives (ACNM #2024-NUTR-012).

Sigrun is manufactured in a FDA-registered facility in Monterey, CA, and distributed exclusively through licensed U.S. pharmacies. It is not available for direct-to-consumer purchase online or in retail stores—a safeguard ensuring appropriate clinical use and monitoring.

Finally, while Sigrun addresses three critical nutrient gaps, it does not contain iodine (150 mcg recommended daily) or calcium (1,000 mg/day). Patients should continue separate iodized salt use and dairy or fortified plant-milk intake unless otherwise directed. These remain essential components of comprehensive prenatal nutrition—neither replaced nor duplicated by Sigrun’s targeted formulation.